Suppr超能文献

开发一种具有增强附着性的成膜性油凝胶,用于治疗银屑病。

Development of a film-forming oleogel with increased substantivity for the treatment of psoriasis.

机构信息

Department of Pharmaceutical Technology, Eberhard Karls University, Auf der Morgenstelle 8, 72076 Tübingen, Germany.

Department of Pharmaceutical Technology, Eberhard Karls University, Auf der Morgenstelle 8, 72076 Tübingen, Germany.

出版信息

Int J Pharm. 2024 Jun 25;659:124278. doi: 10.1016/j.ijpharm.2024.124278. Epub 2024 May 26.

Abstract

The aim of this work was the development of a film-forming formulation (FFF) for the topical treatment of psoriasis that shows an increased substantivity compared to conventional semi-solid dosage forms. The developed formulation is an oleogel. It is based on a combination of castor oil and medium chain triglycerides, and the oil-soluble film former MP-30 (Croda GmbH, Nettetal, Germany), a polyamide that upon mixing with a polar oil entraps the oil und thus substantially increases the viscosity of the formulation up to a semisolid state. Betamethasone dipropionate (BDP) and calcipotriole (CA) were used as active pharmaceutical ingredients (APIs). Oleogels of different compositions were evaluated regarding substantivity, rheological properties, ex-vivo penetration into the skin and ex-vivo permeation through the skin. Marketed products were used as controls. It was found that the amount of betamethasone dipropionate penetrating and permeating into and through the skin from the film-forming formulation is at an intermediate value compared to the marketed products. The substantivity of the developed formulation is described by an amount of 57.7 % formulation that remains on the skin surface and is thus significantly higher compared to the marketed products. In the film forming formulation, the proportion of API penetrating the skin remains the same when the skin repetitively brought in contact with a piece of textile during the penetration experiment. In contrast with the in-market formulations tested, this proportion was reduced by up to 97 %. As a result, the developed formulations can lead to an increased patient compliance.

摘要

本工作旨在开发一种用于治疗银屑病的成膜制剂(FFF),与传统半固体制剂相比,该制剂具有更高的持续性。所开发的制剂是一种油凝胶。它基于蓖麻油和中链甘油三酯的组合,以及油溶性成膜剂 MP-30(德国 Nettetal 的 Croda GmbH),一种聚酰胺,与极性油混合时会捕获油,从而大大增加制剂的粘度至半固态。倍他米松二丙酸酯(BDP)和卡泊三醇(CA)用作活性药物成分(APIs)。不同组成的油凝胶在持续性、流变性能、体外渗透进入皮肤和体外透过皮肤方面进行了评估。市售产品用作对照。结果发现,与市售产品相比,从成膜制剂中渗透和透过皮肤进入皮肤的倍他米松二丙酸酯的量处于中间值。所开发制剂的持续性通过留在皮肤表面的 57.7%制剂来描述,与市售产品相比显著更高。在成膜制剂中,当皮肤在渗透实验中反复与一块纺织品接触时,穿透皮肤的 API 比例保持不变。与测试的市售制剂相反,该比例降低了多达 97%。因此,所开发的制剂可以提高患者的顺应性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验